Cargando…

Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy

Cancer immunotherapy has made rapid progress over the past decade leading to high enthusiasm and interest worldwide. Codelivery of immunomodulators with chemotherapeutic agents and radioisotopes has been shown to elicit a strong and sustained immune response in animal models. Despite showing promisi...

Descripción completa

Detalles Bibliográficos
Autores principales: Selvaraja, Vinodh Kumar, Gudipudi, Deleep Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532032/
https://www.ncbi.nlm.nih.gov/pubmed/33082845
http://dx.doi.org/10.3332/ecancer.2020.1095
_version_ 1783589838909341696
author Selvaraja, Vinodh Kumar
Gudipudi, Deleep Kumar
author_facet Selvaraja, Vinodh Kumar
Gudipudi, Deleep Kumar
author_sort Selvaraja, Vinodh Kumar
collection PubMed
description Cancer immunotherapy has made rapid progress over the past decade leading to high enthusiasm and interest worldwide. Codelivery of immunomodulators with chemotherapeutic agents and radioisotopes has been shown to elicit a strong and sustained immune response in animal models. Despite showing promising results in metastatic and recurrent cancers, the utilisation of immunotherapy in clinical settings has been limited owing to uncertainties in elicited immune response and occurrence of immune-related adverse events. These uncertainties can be overcome with the help of nanoparticles possessing unique properties for the effective delivery of targeted agents to specific sites. Nanoparticles play a crucial role in the effective delivery of cancer antigens and adjuvants, modulation of tumour microenvironment, production of long-term immune response and development of cancer vaccines. Here, we provide a comprehensive summary of nanotechnology-based cancer immunotherapy and radiotherapy including basics of nanotechnology, properties of nanoparticles and various methods of employing nanoparticles in cancer treatment. Thus, nanotechnology is anticipated to overcome the limitations of existing cancer immunotherapy and to effectively combine various cancer treatment modalities.
format Online
Article
Text
id pubmed-7532032
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-75320322020-10-19 Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy Selvaraja, Vinodh Kumar Gudipudi, Deleep Kumar Ecancermedicalscience Review Cancer immunotherapy has made rapid progress over the past decade leading to high enthusiasm and interest worldwide. Codelivery of immunomodulators with chemotherapeutic agents and radioisotopes has been shown to elicit a strong and sustained immune response in animal models. Despite showing promising results in metastatic and recurrent cancers, the utilisation of immunotherapy in clinical settings has been limited owing to uncertainties in elicited immune response and occurrence of immune-related adverse events. These uncertainties can be overcome with the help of nanoparticles possessing unique properties for the effective delivery of targeted agents to specific sites. Nanoparticles play a crucial role in the effective delivery of cancer antigens and adjuvants, modulation of tumour microenvironment, production of long-term immune response and development of cancer vaccines. Here, we provide a comprehensive summary of nanotechnology-based cancer immunotherapy and radiotherapy including basics of nanotechnology, properties of nanoparticles and various methods of employing nanoparticles in cancer treatment. Thus, nanotechnology is anticipated to overcome the limitations of existing cancer immunotherapy and to effectively combine various cancer treatment modalities. Cancer Intelligence 2020-09-01 /pmc/articles/PMC7532032/ /pubmed/33082845 http://dx.doi.org/10.3332/ecancer.2020.1095 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Selvaraja, Vinodh Kumar
Gudipudi, Deleep Kumar
Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy
title Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy
title_full Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy
title_fullStr Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy
title_full_unstemmed Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy
title_short Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy
title_sort fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532032/
https://www.ncbi.nlm.nih.gov/pubmed/33082845
http://dx.doi.org/10.3332/ecancer.2020.1095
work_keys_str_mv AT selvarajavinodhkumar fundamentalstoclinicalapplicationofnanoparticlesincancerimmunotherapyandradiotherapy
AT gudipudideleepkumar fundamentalstoclinicalapplicationofnanoparticlesincancerimmunotherapyandradiotherapy